{"entity":{"id":"dnx-2440","kind":"drug","name":"DNX-2440","aka":[],"tldr":"DNX-2440 is an experimental oncolytic adenovirus from DNAtrix, in phase 1 trials for colorectal cancer liver metastases, liver metastases from other solid tumours and recurrent glioblastoma; development is paused.","summary":"DNX-2440 is an oncolytic adenovirus from DNAtrix. An oncolytic adenovirus expressing OX40 ligand, a costimulatory molecule expected to enhance T-cell responses against the tumour. Its furthest stage is phase 1, for colorectal cancer liver metastases, liver metastases from other solid tumours and recurrent glioblastoma. ClinicalTrials.gov registers it in 2 studies linked below. NCT04714983 (DNAtrix, liver metastases) is SUSPENDED: 'DNAtrix management decision not based on study design, safety, or site performance.' NCT03714334 (Navarra, recurrent glioblastoma) TERMINATED: 'Break of stock'. Registry checked 3 Nov 2026. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"DNAtrix: biospace.com","url":"https://www.biospace.com/dnatrix-announces-first-patient-dosed-in-clinical-study-of-dnx-2440-an-ox40-ligand-expressing-immunotherapy-in-colorectal-cancer-and-other-cancers-with-liver-metastasis"},{"label":"DNAtrix: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT04714983"},{"label":"ClinicalTrials.gov: trials of DNX-2440","url":"https://clinicaltrials.gov/search?intr=DNX-2440"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["dnatrix"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04714983","nct03714334"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"DNX-2440","modality":"Oncolytic adenovirus","mechanism":"An oncolytic adenovirus expressing OX40 ligand, a costimulatory molecule expected to enhance T-cell responses against the tumour.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/dnx-2440/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"dnatrix","kind":"company","name":"DNAtrix","route":"/companies/dnatrix/"}],"trial":[{"id":"nct04714983","kind":"trial","name":"DNX-2440 for Resectable Colorectal Liver Metastasis","route":"/trials/nct04714983/"},{"id":"nct03714334","kind":"trial","name":"DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma","route":"/trials/nct03714334/"}]}}